This page is historical material reflecting the Feedback Loop Blog as it existed on September 18, 2009. This page is no longer updated and links to external websites and some internal pages may not work.
September 18, 2009

Archived: Nearly Half of NIGMS Recovery Act Funds Now Awarded

By Jeremy Berg
Three weeks ago, I posted a graph of the cumulative investment of NIGMS Recovery Act funds as a function of the award start date. Below is an updated version.

This graph shows that the rate at which we have made Recovery Act awards from July to September has accelerated.

This graph differs from my previous one in two ways. First, it is up to date as of yesterday. Second, it includes commitments for the second year of awarded 2-year R01 grants. As it shows, we are close to allocating half of our $505 million of Recovery Act funds. We are making more awards every day, with the Challenge grants, GO grants, and faculty start-up (P30) grants to be awarded soon. The awards made to date can be broken down into seven major categories.

This graph shows the amount and total number of awards in each category. R01: 112. R01 equivalent supplements: 511. AREA grants (R15): 11. AREA grants supplements: 22. MBRS SCORE (S06, SC1,2,3, R25) supplements: 77. MARC (T34) supplements. Research training grant (T32) supplements: 90.

This graph shows the amount and total number of awards (blue type above each bar) in each category. The gray-shaded area over the R01 category reflects second-year commitments. To put these figures in context, NIGMS currently supports approximately 3,600 R01 grants; 50 AREA (R15) grants; 250 Minority Biomedical Research Support (MBRS) S06, SC1, SC2, SC3, and R25 grants; 50 Minority Access to Research Careers (MARC) T34 grants; and 300 institutional research training T32 grants. We will continue to update you on our Recovery Act activities as we move from one fiscal year to the next at the end of this month.
topic Director’s Messages , Funding Trends

About the Author

Jeremy Berg

As former NIGMS director, Jeremy oversaw the Institute’s programs to fund biomedical research and to train the next generation of scientists. He was a leader in many NIH-wide activities and also found time to study a variety of molecular recognition processes in his NIH lab.